edoc

Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count

Mocroft, Amanda and Reiss, Peter and Kirk, Ole and Mussini, Cristina and Girardi, Enrico and Morlat, Philippe and Stephan, Christoph and De Wit, Stephane and Doerholt, Katja and Ghosn, Jade and Bucher, Heiner C. and Lundgren, Jens D. and Chene, Genevieve and Miro, Jose M. and Furrer, Hansjakob. (2010) Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count. Clinical infectious diseases, Vol. 51, H. 5. pp. 611-619.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A6004318

Downloads: Statistics Overview

Abstract

Current guidelines suggest that primary prophylaxis for Pneumocystis jiroveci pneumonia (PcP) can be safely stopped in human immunodeficiency virus (HIV)-infected patients who are receiving combined antiretroviral therapy (cART) and who have a CD4 cell count <200 cells/microL. There are few data regarding the incidence of PcP or safety of stopping prophylaxis in virologically suppressed patients with CD4 cell counts of 101-200 cells/microL.
Faculties and Departments:03 Faculty of Medicine > Departement Klinische Forschung > Clinical Epidemiology and Biostatistics CEB > Klinische Epidemiologie (Bucher H)
UniBasel Contributors:Bucher, Heiner C.
Item Type:Article, refereed
Article Subtype:Research Article
Bibsysno:Link to catalogue
Publisher:Oxford University Press
ISSN:1058-4838
Note:Publication type according to Uni Basel Research Database: Journal article
Related URLs:
Identification Number:
Last Modified:07 Dec 2012 13:03
Deposited On:07 Dec 2012 12:59

Repository Staff Only: item control page